<DOC>
	<DOCNO>NCT02638129</DOCNO>
	<brief_summary>The purpose study evaluate cardiovascular ( CV ) safety naltrexone hydrochloride ( HCl ) bupropion HCl extend release combination ( NB ) compare placebo rule excess risk major adverse cardiovascular event ( MACE ) give combination standard care overweight obese participant document history CV disease .</brief_summary>
	<brief_title>Naltrexone/Bupropion Cardiovascular Outcomes Study</brief_title>
	<detailed_description>The drug evaluate study naltrexone hydrochloride ( HCl ) bupropion HCl extend release combination ( NB ) . NB evaluate study rule excess cardiovascular risk . This study evaluate occurrence major adverse CV event participant take NB compare placebo give combination standard care overweight obese participant document history CV disease . The study enroll approximately 8800 patient . After 2-week lead-in period evaluate tolerance NB ( participant randomly assign 1:1 ratio 1 week NB [ 1 tablet per day ] follow 1 week placebo [ 1 tablet per day ] 1 week placebo follow 1 week NB ) , participant randomly assign one two treatment group 1:1 ratio , remain undisclosed patient , study site personnel , investigator/study physician study ( unless urgent medical need ) : - Naltrexone HCl 8 mg/bupropion 90 mg extend release combination tablet - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient All participants ask take tablet ( ) AM PM time day throughout study . This multi-center trial conduct United States . The overall time participate study 6 year . Participants make multiple visit clinic , contact telephone 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . Participant sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has body mass index ( BMI ) ≥27.0 kg/m^2 Screening . 4 . Is male female age ≥18 year Screening . 5 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent 12 week last dose study medication . 6 . Participant meet least 1 follow category cardiovascular ( CV ) disease ( ac ) : 1 . Documented coronary artery disease ( least 1 follow 2 criterion must satisfy ) : 1 . A documented history myocardial infarction ( MI ) occur great 3 month prior Screening . 2 . History coronary revascularization least 1 follow : 1 . Coronary artery bypass graft surgery occur great 3 month prior Screening . 2 . Percutaneous coronary intervention ( PCI ) occur great 3 month prior Screening . 2 . Documented peripheral arterial disease ( least 1 follow 3 criterion must satisfy ) : 1 . Current intermittent claudication verify ischemic ulcer ( ) together document anklebrachial index ≤0.85 . 2 . History previous vascular intervention intermittent claudication rest limb ischemia great 3 month prior Screening ( example : amputation arterial disease , peripheral bypass , history angioplasty/stenting ) . 3 . History symptomatic carotid artery disease ( require revascularization carotid endarterectomy stenting ) great 3 month prior Screening ≥50 % stenosis least one carotid artery document duplex ultrasonography , magnetic resonance angiography , compute tomographic angiography , catheterbased contrast angiography . 3 . Documented cerebrovascular disease ( least 1 follow 2 criterion must satisfy ) : 1 . A history transient ischemic attack confirm neurologist great 3 month prior Screening clinically neurologically stable Screening . 2 . A history ischemic stroke ( Modified Rankin Scale Score ≤3 ) great 3 month prior Screening clinically neurologically stable Screening . 1 . Has receive investigational compound investigational device within 3 month prior Screening . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . Has MI unstable angina within 3 month Screening . 4 . Has plan bariatric surgery , cardiac surgery , coronary revascularization , peripheral artery revascularization . 5 . Has history bariatric surgery ( eg , RouxenY gastric bypass , duodenal switch , sleeve gastrectomy ) . 6 . Has procedure weight loss bariatric surgery ( eg , gastric banding device maybe use obesity treatment ) within past 12 month prior Screening . 7 . Has history hypersensitivity allergy component naltrexone hydrochloride ( HCl ) bupropion HCl extend release combination ( NB ) excipients . 8 . Has history cancer remission &lt; 5 year prior Screening . A history basal cell carcinoma Stage 1 squamous cell carcinoma skin allow . 9 . Is hemodynamically unstable , include severe heart failure ( New York Heart Association Class IV ) Screening . 10 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior Screening . 11 . Has randomize previous NB ( Contrave ) study expose commercially available NB ( Contrave ) period time prior Screening . 12 . Is take excluded medication within 28 day Screening . 13 . Has uncontrolled hypertension define systolic blood pressure ( SBP ) ≥160 mm Hg and/or ≥100 mm Hg diastolic blood pressure ( DBP ) average two seated blood pressure measurement rest least 5 minute , confirm 2 separate day Screening Period . 14 . Has severe renal impairment define estimate glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73 m^2 base Chronic Kidney Disease Epidemiology Collaboration equation ( CKDEPI ) Screening . 15 . Has clinical history liver failure . 16 . Has know infection human immunodeficiency virus treat ritonavir , lopinavir efavirenz . 17 . Has know acute hepatitis Screening . 18 . Has chronic use opioids , define longer 3 month prior Screening . 19 . Has positive drug screen cocaine , methamphetamine , methadone , opiates , oxycodone , phencyclidine , propoxyphene Screening . A positive screen amphetamine , barbiturate , benzodiazepine , cannabinoids exclusionary abuse dependence suspect . 20 . Has history seizure ( include febrile seizure ) , cranial trauma , condition predispose participant seizure . 21 . Has history mania , history current diagnosis bipolar disorder current diagnosis active psychosis , active bulimia anorexia nervosa ( binge eat disorder exclusionary ) . 22 . Is risk suicide attempt base judgment investigator . 23 . If female , participant pregnant ( confirmed laboratory test screen ) lactate intend become pregnant signing inform consent 12 week last dose study medication ; intend donate ova time period . 24 . Has history severe ischemic stroke ( Modified Rankin Scale Score ≥4 ) . 25 . Has major illness condition , investigator 's opinion , prohibit participant participate study meeting plan visit schedule . 26 . Is unable understand verbal write English language , certified translation approve informed consent available . Additional exclusion criterion assess Visit3 prior Randomization : 1 . Participant take &lt; 75 % &gt; 125 % Leadin study medication . 2 . Participant discontinues study medication treatment know major adverse cardiovascular event ( MACE ) report investigator DoubleBlind Leadin Period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>